Activating mutations in BRAF, such as BRAFV600E can lead to aberrant MAPK signalling and proliferation in human tumors including melanoma, papillary thyroid carcinoma, and gastrointestinal stromal tumor [1-3]. This evidence concerns the gene BRAF and melanoma.